RecruitingPhase 1NCT05218850

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

Butyrate Therapy in Hispanic Children With Ulcerative Colitis

Sponsor

Children's Hospital Los Angeles

Enrollment

10 participants

Start Date

Jun 29, 2022

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis

Summary

Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.

Eligibility

Min Age: 7 YearsMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether butyrate — a short-chain fatty acid produced naturally by gut bacteria and available as a supplement — can help reduce inflammation and improve symptoms in children and teenagers with mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease that causes chronic inflammation of the large intestine. **You may be eligible if...** - You are between 7 and 21 years old - You have been diagnosed with mild to moderate ulcerative colitis **You may NOT be eligible if...** - You have received any UC treatment within 4 weeks of starting the study medication - You have infectious colitis (bowel inflammation caused by an infection) - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.